Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas.

  title={Chromosomal alterations, prognostic factors, and targeted molecular therapies for malignant meningiomas.},
  author={Andrew Y. Yew and Andy Trang and Daniel Tetsuji Nagasawa and Marko Spasi{\'c} and Winward Choy and Heather M Garcia and Isaac Yang},
  journal={Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia},
  volume={20 1},
Meningiomas are the second most common intracranial neoplasm in adults and originate from arachnoidal cap cells. Malignant meningiomas are resistant to conventional treatments such as surgery, chemotherapy, and radiotherapy. Unlike benign meningiomas, atypical and anaplastic tumors generally display more complex karyotypes associated with aggressive behavior. While these chromosomal anomalies are associated with greater malignancy in meningiomas, the specific genes involved remain unknown… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 10 extracted citations

Systemic therapy for recurrent meningioma.

Expert review of neurotherapeutics • 2016
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 87 references

Meningioma pathology, genetics, and biology.

Journal of neuropathology and experimental neurology • 2004
View 5 Excerpts
Highly Influenced

Bevacizumab-induced regression of anaplastic meningioma.

Annals of oncology : official journal of the European Society for Medical Oncology • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…